Trial Profile
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenstrom Macroglobulinemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Ixazomib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 13 Dec 2022 Preliminary results assessing efficacy of ixazomib and ibrutinib in patients with newly diagnosed as well as relapsed/refractory waldenstrom macroglobulinemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 03 Aug 2022 Status changed from suspended to active, no longer recruiting, according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 08 Jul 2021 Status changed from recruiting to suspended due to safety analysis per study design.